Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Component therapy with cryo-poor plasma (CPP)].

J Roewer1, C Dettmann

  • 1Bezirksinstitut für Blutspende- und Transfusionswesen Rostock, DDR.

Beitrage Zur Infusionstherapie = Contributions to Infusion Therapy
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Delphinidin modulates neuroinflammation and behavioral deficits in a Parkinson's disease mouse model.

NPJ Parkinson's disease·2026
Same author

[Preoperative donation of autologous blood and plasma].

Anaesthesiologie und Reanimation·1991
Same author

[Inhibitor hemophilia A--diagnostic and therapeutic significance of controlled substitutions with factor VIII].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1990
Same author

[New aspects of blood component therapy].

Anaesthesiologie und Reanimation·1990
Same author

[When is fresh frozen plasma indicated?].

Anaesthesiologie und Reanimation·1989
Same author

[Status of "blood coagulation active human citrate plasma" within the scope of blood component therapy].

Zeitschrift fur arztliche Fortbildung·1987
Same journal

[Not Available].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Preliminary results of the 2nd multicenter study. Thrombocytapheresis with the Fresenius AS-104 blood cell separator and ring study of cell counting. Section of Therapeutic and Preparative Hemapheresis of the DGTI].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Thrombocyte substitution in hematologic patients].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Substitution of thrombocyte concentrates in polytransfused patients].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Indications for fresh frozen plasma: evaluation of virus inactivating preparations].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
Same journal

[Indications for irradiated blood components: dose and side effects].

Beitrage zur Infusionstherapie = Contributions to infusion therapy·1993
See all related articles

New strategies in blood component therapy are crucial due to increased Fresh Frozen Plasma (FFP) use. Using Cryoprecipitate Pooled Plasma (CPP) instead of FFP may help meet the rising demand for factor VIII in surgery.

Area of Science:

  • Transfusion Medicine
  • Hematology
  • Clinical Trials

Context:

  • Rising demand for Fresh Frozen Plasma (FFP) in clinical practice.
  • Need for alternative blood component therapies.
  • Importance of factor VIII in operative medicine.

Purpose:

  • To explore the use of Cryoprecipitate Pooled Plasma (CPP) as an alternative to FFP.
  • To evaluate the efficacy of CPP in supporting factor VIII levels.
  • To present initial findings from a clinical trial on CPP versus FFP.

Summary:

  • This article discusses the strategic role of national blood programs and the evolving landscape of component therapy.
  • It highlights the increasing utilization of FFP and the necessity for innovative solutions.
  • The study focuses on the potential of CPP as a substitute for FFP, particularly for managing factor VIII demand in surgical patients.

Related Experiment Videos

Impact:

  • Provides preliminary data on the use of CPP in operative settings.
  • Offers insights into optimizing blood component therapy for factor VIII replacement.
  • Contributes to the understanding of alternative strategies for managing blood product shortages and demands.